Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEGIN: ONCE ASIA
NCT01059799Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2010
- Primary completion
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of insulin degludec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Glycosylated Haemoglobin at 26 weeks. Started Feb 2010; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01059799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01059799.